Abstract
During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Current Drug Safety
Title:Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Volume: 11 Issue: 1
Author(s): E. Molinelli, A. Campanati, G. Ganzetti and A. Offidani
Affiliation:
Keywords: Adverse events, immune-mediated inflammatory disease, TNFα inhibitors, TNF biology, Ustekinumab.
Abstract: During the last decades, the advent of biological therapies has revolutionized the management of several immune-mediated inflammatory disorders, as inflammatory bowel diseases, autoimmune arthritis and psoriasis, which significantly impact both quality of life and health care economics. Biological therapies currently available can be divided into two main categories: the tumor necrosis factor-α antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol) and interleukin 12/23 monoclonal antibodies (ustekinumab).
Biologics, reducing TNFα bioavailability or inhibiting proximal regulators of inflammatory cascade, represent an established therapeutic strategy of inflammatory autoimmune diseases, with remarkable efficacy and a safety profile that is extensively examined and monitored.
The biology and the immunological effects of TNFα, IL-12, IL-23 and related signalling pathways are accurately summarized. The dosing regimens, methods of administration, pharmacodynamics profiles, and side effects of the currently licensed TNFα antagonists and IL12/IL23 inhibitor are discussed in detail.
Export Options
About this article
Cite this article as:
Molinelli E., Campanati A., Ganzetti G. and Offidani A., Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666151014115127
DOI https://dx.doi.org/10.2174/1574886310666151014115127 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alopecia Areata
Recent Patents on Inflammation & Allergy Drug Discovery The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics
Current Medicinal Chemistry Microbes, Immunity and Multiple Sclerosis: An Update
Current Immunology Reviews (Discontinued) CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Regulatory T Cells in Severe Drug Eruptions
Current Immunology Reviews (Discontinued) Autoimmune Diseases and Infections: A Controversial Relationship
Current Immunology Reviews (Discontinued) Tuning Immune Suppression in Systemic Autoimmunity with Self-Derived Peptides
Inflammation & Allergy - Drug Targets (Discontinued) Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Vitamin D Receptor as a Drug Discovery Target
Mini-Reviews in Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Autoimmune Diseases in Gastroenterology
Current Pharmaceutical Design Mesenchymal Stromal Cells in Rheumatoid Arthritis: Biological Properties and Clinical Applications
Current Stem Cell Research & Therapy Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued)